An observational study in Urothelial Carcinoma, sponsored by Hoffmann-La Roche. Terminated at 32 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-19.
Sponsored by Hoffmann-La Roche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche — none open to participants now, 1 under way, none of them phase 3. Carcinoma, Transitional Cell · Hoffmann-La Roche.
Among the 12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche, this one is one of 3 that started in 2017, is one of 4 observational ones, and was the 7th registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →None of the 12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche is open now. The open studies under Carcinoma, Transitional Cell, anywhere →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 2
First in 2015; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 300 across 107 observational studies indexed under Carcinoma, Transitional Cell.
Median enrollment 165 across the 7 interventional studies, 890 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 88 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to investigate the effectiveness of Atezolizumab with a primary focus on the overall survival (OS) rate at 2 years and secondary focuses on quality of life (QoL) and the sequence of treatment in mUC patients. Furthermore, this study aims at collecting data on safety of Atezolizumab and on the reason for cisplatin-ineligibility
The study population consists of patients ineligible for palliative cisplatin-based chemotherapy or who received prior adjuvant/ neoadjuvant chemotherapy or chemo radiation with a treatment-free interval more than 12 months (1L)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atezolizumab is administered via IV 1200 mg every 3 weeks
Overall Survival Rate (OS rate)
Time frame: 2 years
Median Overall Survival (OS)
Time frame: Initiation of study treatment until death or end of study, approximately 4 years
Median Progression Free Survival (PFS)
Time frame: Initiation of study treatment to first measured disease progression, through end of study (approximately 4 years)
Percentage of participants with adverse events
Time frame: Up to approximately 4 years
Ran from Dec 2017 to primary completion in Aug 2018, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Transitional Cell →